User Tools

Site Tools

Trace:
pharmatlas:templates:drug_page

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision		Previous revision
pharmatlas:templates:drug_page [2026/02/13 15:39] – andrew2393cnspharmatlas:templates:drug_page [2026/02/13 15:52] (current) – andrew2393cns
Line 1: Line 1:
-<WRAP right 260px> +<WRAP right 280px> 
-{{ :endocrine:biguanides:metformin.svg |{{:images:drugs:drug_name.png?220|Drug Name}}}}+<WRAP infobox> 
 +{{:images:drugs:drug_name_structure.png?220|Drug Name (chemical structure)}}
  
 ^ Drug Name | ^ Drug Name |
-| Brand Names |  | +| Brand Names | Brand1®, Brand2® | 
-| Drug Class | [[class:link_here|Class]] | +| Drug Class | [[namespace:class:start|Class Name]] | 
-| Subclass |  | +| Subclass | [[namespace:class:subclass|Subclass]] | 
-| Route(s) |  |+| Primary Indications | [[disease:page|Indication 1]]; [[disease:page|Indication 2]] | 
 +| Route(s) | Oral / IV / SQ / INH | 
 +| Onset |  | 
 +| Duration |  | 
 +| Metabolism | CYP ___ / none | 
 +| Half-life |  | 
 +| Elimination | Renal / Hepatic / Both |
 | Pregnancy |  | | Pregnancy |  |
-| Renal Adjustment |  | +| Renal Adjustment | Yes / No | 
-| Hepatic Adjustment |  | +| Hepatic Adjustment | Yes / No | 
-| Black Box Warning |  | +| Black Box Warning | Yes / No | 
-| FDA Approval |  |+| Controlled | No / C-II / C-IV | 
 +| FDA Approval | YYYY | 
 +</WRAP>
 </WRAP> </WRAP>
  
-====== Drug Name ======+====== Generic (Brand®) ======
  
-<span class="badge badge-endo">Endocrine</span> 
 <span class="badge badge-common">Common</span> <span class="badge badge-common">Common</span>
 +<span class="badge badge-firstline">First-line</span>
 +<!-- Optional: <span class="badge badge-bbw">Black Box</span> -->
 +<!-- Optional: <span class="badge badge-qt">QT Risk</span> -->
  
 ===== Overview ===== ===== Overview =====
-1–3 sentence “what it is / why we use it.”+One tight paragraph: 
 +  * What the drug is 
 +  * Where it fits clinically (first-line vs add-on) 
 +  * The “why it matters” outcome or key role
  
 ===== Mechanism of Action ===== ===== Mechanism of Action =====
-Explain mechanistically.+  * Primary target (receptor/enzyme/transporter): 
 +  * Downstream signal/pathway: 
 +  * Net physiologic effect (what variable changes): 
 +  * Why that helps the disease state:
  
 ===== Indications ===== ===== Indications =====
-  * [[disease:link|Indication 1]] +  * [[disease:page|Indication 1]] 
-  * [[disease:link|Indication 2]]+  * [[disease:page|Indication 2]] 
 +  * Common off-label: 
 +    * [[disease:page|Off-label 1]]
  
-<WRAP details> +<WRAP blackbox> 
-===== Pharmacokinetics ===== +===== Black Box Warning ===== 
-  * Absorption: +  * (If none, delete this entire blackbox section.) 
-  * Metabolism: +</WRAP> 
-  * Half-life: + 
-  * Elimination:+<WRAP contra> 
 +===== Contraindications ===== 
 +Absolute: 
 +  *  
 +Relative / Cautions: 
 +  * 
 </WRAP> </WRAP>
  
 <WRAP details> <WRAP details>
 ===== Dosing ===== ===== Dosing =====
-  * Adult: +Adult: 
-  * Renal: +  * Starting dose: 
-  * Hepatic:+  * Typical dose: 
 +  * Max dose: 
 +Titration: 
 +  *  
 +Renal dosing: 
 +  *  
 +Hepatic dosing: 
 +  *  
 +Special populations: 
 +  * Elderly: 
 +  * Pregnancy:
 </WRAP> </WRAP>
  
-<span class="badge badge-bbw">BLACK BOX WARNING</span>+<WRAP details> 
 +===== Pharmacokinetics ===== 
 +Absorption: 
 +  *  
 +Bioavailability: 
 +  *  
 +Protein binding: 
 +  *  
 +Distribution: 
 +  *  
 +Metabolism: 
 +  * [[cyp:start|CYP pathways]] (if relevant) 
 +Half-life: 
 +  *  
 +Elimination: 
 +  * Renal / Hepatic / Both 
 +</WRAP>
  
 <WRAP details> <WRAP details>
Line 52: Line 102:
 Serious: Serious:
   *    * 
-</WRAP> +Mechanism-based:
- +
-<WRAP details> +
-===== Contraindications =====+
   *    * 
 </WRAP> </WRAP>
Line 61: Line 108:
 <WRAP details> <WRAP details>
 ===== Drug Interactions ===== ===== Drug Interactions =====
 +CYP:
 +  * Inhibitors:
 +  * Inducers:
 +Additive physiologic effects:
 +  * 
 +High-yield “do not miss”:
   *    * 
 </WRAP> </WRAP>
  
-<WRAP details>+<WRAP monitoring>
 ===== Monitoring ===== ===== Monitoring =====
 +Vitals:
 +  * 
 +Labs:
 +  * 
 +ECG (if relevant):
 +  * 
 +Clinical response:
   *    * 
 </WRAP> </WRAP>
Line 72: Line 132:
 ===== Clinical Pearls ===== ===== Clinical Pearls =====
   *    * 
-</WRAP> 
- 
-<WRAP blackbox> 
-===== Black Box Warning ===== 
-**RISK:** 
   *    * 
   *    * 
 </WRAP> </WRAP>
 +
 +===== Comparison Within Class =====
 +  * How it differs from others in [[namespace:class:start|Class Name]]:
 +    * potency / selectivity:
 +    * duration:
 +    * renal vs hepatic clearance:
 +    * outcome evidence:
 +    * “best use case” patient:
  
 ===== Related ===== ===== Related =====
-  * [[class:start|Class page]] +  * [[namespace:class:start|Class: Class Name]] 
-  * [[module:start|Module landing page]]+  * [[module:start|Module Landing Page]] 
 +  * [[endocrine:start|Endocrine Pharmacology]] (or [[cardio:intro:start|Cardiovascular Pharmacology]])
pharmatlas/templates/drug_page.1770997146.txt.gz · Last modified: by andrew2393cns